Secondary outcome
All parameters were evaluated on day 0 (baseline) and 8th week (follow-up) of the intervention and the fasting blood samples were obtained at 8 am in the morning.Alterations in cellular and molecular markers including: (a) T cell subset population: Th17 (CD3+ CD4+ IL17+ RORγt+) cells and Treg (CD3+ CD4+ CD25+ CD127− Foxp3+) cells, (b) markers of immune aging: aged Th17 (CD3+ CD4+ IL17+ RORγt+ CD28−) cells and aged Treg (CD3+ CD4+ CD25+ CD127− Foxp3+ CD28−) cells, (c) inflammatory markers: IL-6, IL-17, TGF-β, and IL-10 (d) epigenetic alterations: 5-methyl cytosine, 5-hydroxymethyl cytosine and HDAC1, and (e) gene expression levels: 